Novartis reports on MEASURE 1 and MEASURE 2 trials of AIN 457 for Ankylosing Spondylitis

Novartis has announced results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN 457 (secukinumab) in Ankylosing Spondylitis (AS). In the studies, secukinumab met the primary endpoint demonstrating rapid and statistically significant improvements versus placebo in the signs and symptoms of AS. More than 60% of secukinumab 150 mg patients achieved an ASAS20 response, a standard tool used to assess clinical improvement in AS, in MEASURE 1 (p<0.0001) and measure 2 (p><0.001) this is in comparison to 28.7% and 28.4% of placebo patients who achieved asas20 in measure 1 and measure 2, respectively. detailed study results will be presented during a plenary session (measure 1) and in a late breaker poster presentation (measure 2) at the american college of rheumatology (acr) congress in boston, usa.>